- Home
- CNTY vs TLPH Comparison
CNTY vs TLPH Comparison
Compare CNTY & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | TLPH |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | 3756 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 42.3M |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CNTY | TLPH |
|---|---|---|
| Price | $1.40 | $0.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 71.1K | ★ 131.5K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | $2,151,000.00 |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.23 | $0.38 |
| 52 Week High | $2.85 | $1.57 |
Technical Indicators
Market Signals| Indicator | CNTY | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 44.52 |
| Support Level | $1.40 | $0.73 |
| Resistance Level | $1.47 | $0.87 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 74.80 | 19.13 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.